Author:
von Mach Marc A,Burhenne Jürgen,Weilemann Ludwig S
Publisher
Springer Science and Business Media LLC
Subject
Pharmacology (medical),Pharmacology
Reference13 articles.
1. Herbrecht R, Denning DW, Patterson TF, Bennett JE, Greene RE, Oestmann JW, Kern WV, Marr KA, Ribaud P, Lortholary O, Sylvester R, Rubin RH, Wingard JR, Stark P, Durand C, Caillot D, Thiel E, Chandrasekar PH, Hodges MR, Schlamm HT, Troke PF, de Pauw B, Invasive Fungal Infections Group of the European Organisation for Research andTreatment of Cancer and the Global Aspergillus Study Group: Voriconazole versus amphotericin B for primary therapy of invasive aspergillosis. N Engl J Med. 2002, 347: 408-415. 10.1056/NEJMoa020191.
2. Kullberg BJ, Sobel JD, Ruhnke M, Pappas PG, Viscoli C, Rex JH, Cleary JD, Rubinstein E, Church LW, Brown JM, Schlamm HT, Oborska IT, Hilton F, Hodges MR: Voriconazole versus a regimen of amphotericin B followed by fluconazole for candidaemia in non-neutropenic patients: a randomised non-inferiority trial. Lancet. 2005, 366: 1435-1442. 10.1016/S0140-6736(05)67490-9.
3. Walsh TJ, Viviani MA, Arathoon E, Chiou C, Ghannoum M, Groll AH, Odds FC: New targets and delivery systems for antifungal therapy. Med Mycol. 2000, 38 (Suppl 1): 335-347.
4. FDA Antiviral Drugs Advisory Committee – Briefing Document for Voriconazole (Oral and Intravenous Formulations). [ http://www.fda.gov/ohrms/dockets/ac/01/briefing/3792b2_01_Pfizer.pdf ]
5. Background Document for the Antiviral Drug Products Advisory Committee Meeting. [ http://www.fda.gov/ohrms/dockets/ac/01/briefing/3792b2_02_FDA-voriconazole.htm ]
Cited by
85 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献